DIGOXINE IN PATIENTS WITH CHRONIC HEART FAILURE: PRO AND CONTRA
- Authors: Melekhov A.V.1, Gendlin G.E1
-
Affiliations:
- «The N.I. Pirogov Russian National Research Medical University»
- Issue: Vol 24, No 4 (2018)
- Pages: 191-194
- Section: Articles
- URL: https://journals.rcsi.science/0869-2106/article/view/38460
- DOI: https://doi.org/10.18821/0869-2106-2018-24-4-191-194
- ID: 38460
Cite item
Full Text
Abstract
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
Alexander V. Melekhov
«The N.I. Pirogov Russian National Research Medical University»
Email: avmelekhov@gmail.com
candidate of medical sciences, associate professor of internal disease chair № 2, “The N.I. Pirogov Russian National Research Medical University”, 117997, Moscow, Russian Federation 117997, Moscow, Russian Federation
G. E Gendlin
«The N.I. Pirogov Russian National Research Medical University»117997, Moscow, Russian Federation
References
- Мареев В.Ю., Агеев Ф.Т., Арутюнов Г.П., Коротеев А.В., Мареев Ю.В., Овчинников А.Г. и др. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр). Сердечная недостаточность. 2013; 14; 7(81): 379-472. УДК 616.12-008.46-036.12 (083.13)
- Ponikowski P., Voors A.A., Anker S.D., Bueno H., Cleland J.G.F., Coats A.J.S., и др. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2016;37(27):2129-200. doi: 10.1093/eurheartj/ehw128
- Yancy C.W., Jessup M., Bozkurt B., Butler J., Casey D.E. Jr., Drazner M.H. et al. American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of CardiologyFoundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;15;62(16):e147-239. doi: 10.1016/j.jacc.2013.05.019.
- Gheorghiade M., Ferguson D. Digoxin: a neurohormonal modulator in heart failure? Circulation. 1991;84 (5): 2181-2186. PMID: 1834367
- Нарусов О.Ю., Мареев В.Ю., Скворцов А.А. и др. Клинические, гемодинамические и нейрогормональные эффекты дигоксина у больных ХСН. Сердечная недостаточность. 2000; 1(1): 26-30
- Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J. Med. 1997;336:525-533. doi: 10.1056/NEJM199702203360801
- Gheorghiade M., Patel K., Filippatos G., Anker S.D., van Veldhuisen D.J., Cleland J.G., Metra M., Aban I.B., Greene S.J., Adams K.F., McMurray J.J., Ahmed A. Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial. Eur J Heart Fail. 2013 May;15(5):551-9. doi: 10.1093/eurjhf/hft010.
- Rathore S.S., Curtis J.P., Wang Y. et al. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA. 2003; 289 (7):871-878. PMID: 12588271
- Hashim T., Elbaz S., Patel K., Morgan C.J., Fonarow G.C., Fleg J.L., McGwin G., Cutter G.R., Allman R.M., Prabhu S.D., Zile M.R., Bourge R.C., Ahmed A. Digoxin and 30-day all-cause hospital admission in older patients with chronic diastolic heart failure. Am J Med. 2014 Feb; 127(2): 132-9. doi: 10.1016/j.amjmed.2013.08.006.
- Ouyang A-J., Lv Y-N., Zhong H-L., Wen J-H., Wei X-H., Peng H-W., Zhou J., Liu L-L. Meta-analysis of digoxin use and risk of mortality in patients with atrial fibrillation. Am J. Cardiol. 2015;115:901-906. doi: 10.1016/j.amjcard.2015.01.013
- Vamos M., Erath J.W., Hohnloser S.H. Digoxin-associated mortality: a systematic review and meta-analysis of the literature. Eur Heart J. 2015;36:1831-1838. doi: 10.1093/eurheartj/ehv143
- Ziff O.J., Lane D.A., Samra M., Griffith M., Kirchhof P., Lip GYH, Steeds R.P., Townend J., Kotecha D. Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. BMJ. 2015;351:h4451. PMCID: PMC4553205.
- Jorge E., Baptista R., Martins H,. Saraiva F., Costa S., Vieira H., Coelho L., Monteiro P., Franco F., Providência L.A. Digoxin in advanced heart failure patients: a question of rhythm. Rev Port Cardiol. 2013 Apr;32(4):303-10. doi: 10.1016/j.repc.2012.11.007.
- Vamos M., Erath J.W., Hohnloser S.H. Digoxin-associated mortality: a systematic review and meta-analysis of the literature. Eur Heart J. 2015;36:1831-1838. doi: 10.1093/eurheartj/ehv143
- Mulder B.A., Van Veldhuisen D.J., Crijns HJGM, Tijssen J.G.P., Hillege H.L., Alings M., Rienstra M., Groenveld H.F., Van den Berg M.P., Van Gelder I.C. RACE II investigators. Lenient vs. strict rate control in patients with atrial fibrillation and heart failure: a post-hoc analysis of the RACE II study. Eur J Heart Fail. 2013;15:1311-1318. doi: 10.1093/eurjhf/hft093
- Bavishi C., Khan A.R., Ather S. Digoxin in patients with atrial fibrillation and heart failure: a meta-analysis. Int J Cardiol. 2015;188:99-101. doi: 10.1016/j.ijcard.2015.04.031
- Freeman J.V., Reynolds K., Fang M., Udaltsova N., Steimle A., Pomernacki N.K., Borowsky L.H., Harrison T.N., Singer D.E., Go A.S. Digoxin and risk of death in adults with atrial fibrillation: the ATRIA-CVRN Study. Circ Arrhythmia Electrophysiol. 2015;8:49-58. doi: 10.1161/CIRCEP.114.002292
- Washam J.B., Stevens S.R., Lokhnygina Y., Halperin J.L., Breithardt G, Singer D.E., Mahaffey KW., Hankey GJ., Berkowitz S.D., Nessel C.C., Fox K.A.A., Califf R.M., Piccini J.P., Patel M.R. Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Lancet. 2015; 385: 2363-2370. doi: 10.1016/S0140-6736(14)61836-5.
- Rienstra M., Damman K., Mulder B.A., Van Gelder I.C., McMurray J.J., Van Veldhuisen D.J. Beta-blockers and outcome in heart failure and atrial fibrillation: a meta-analysis. JACC Heart Fail. 2013 Feb;1(1):21-8. doi: 10.1016/j.jchf.2012.09.002.
- Gheorghiade M., Fonarow G.C., van Veldhuisen D.J., Cleland J.G., Butler J., Epstein A.E., Patel K., Aban I.B., Aronow W.S., Anker S.D., Ahmed A. Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial. Eur Heart J. 2013 May;34(20):1489-97. doi: 10.1093/eurheartj/eht120.
- Adams K.F., Patterson J.H., Gattis W.A. et al. Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis. J. Am Coll Cardiol. 2005;46 (3):497-504. doi: 10.1016/j.jacc.2005.02.091
- Oncu S., Gelal A., Aslan O., Ucku R.S. Appropriateness of digoxin measurement in hospitalized patients. Biochem Med (Zagreb). 2018 Feb 15;28(1):010901. doi: 10.11613/BM.2018.010901.
- Lin Y., He S., Feng R., Xu Z., Chen W., Huang Z., Liu Y., Zhang Q., Zhang B., Wang K., Wu. S. Digoxin-induced anemia among patients with atrial fibrillation and heart failure: clinical data analysis and drug-gene interaction network. Oncotarget. 2017; 8(34): 57003-57011. doi: 10.18632/oncotarget.18504.
Supplementary files
